Prosecution Insights
Last updated: October 04, 2026

Tokyo University of Pharmacy and Life Sciences

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Tokyo University of Pharmacy and Life Sciences has 1 pending office action currently active within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and is situated within 1 distinct art unit. Such a concentrated profile indicates that the company's current patenting efforts are not spread across different examination groups, which simplifies the tracking of procedural requirements but increases reliance on a single examiner's interpretation of the prior art.

The busiest examiner for Tokyo University of Pharmacy and Life Sciences is COFFA, SERGIO, who is responsible for the 1 busiest examiner pending office action. With 1 distinct examiner managing the entire pending portfolio, the prosecution outcomes are tied directly to this individual's specific standards. Practitioners should note that the 1 distinct art unit involved provides a stable environment for prosecution, as the company is not currently navigating the varying internal policies of multiple USPTO divisions. This singular focus on 1 pending office action suggests an early-stage or highly specialized intellectual property strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
COFFA, SERGIO 1 61.1% +32.5%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17442797 CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION COFFA, SERGIO —

Top Art Units

Art UnitApps
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17442797 CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION COFFA, SERGIO 1658 §103 Final Rejection — Pending Jan 27, 2022

Managing Tokyo University of Pharmacy and Life Sciences's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month